Literature DB >> 10798303

Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection.

S Härtter1, H Weigmann, C Hiemke.   

Abstract

A fully automated method including column-switching and isocratic high-performance liquid chromatography (HPLC) was developed for quantitative analysis of the new antidepressant reboxetine, a noradrenaline reuptake inhibitor. After serum injection into the HPLC system and on-line sample clean-up on a silica C8 (10x4.0 mm I.D.) clean-up column with an eluent consisting of 2.5% acetonitrile in deionized water, the chromatographic separation was performed on an analytical column (Lichrospher CN; 250x4.6 mm I.D.) with an eluent of acetonitrile-aqueous potassium phosphate buffer (0.008 M, pH 6.4) (50:50). The UV detector was set at 273 or 226 nm. The limit of quantification was about 15 ng/ml at 273 nm and about 4 ng/ml at 226 nm. The day-to-day relative standard deviation ranged between 2.7 and 6.7% with recovery rates > or = 90%. Linear regression analyses revealed correlation coefficients > 0.998. The method can be applied to therapeutic drug monitoring of reboxetine as well as pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10798303     DOI: 10.1016/s0378-4347(00)00040-2

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  3 in total

Review 1.  Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?

Authors:  Christoph Hiemke
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

2.  The Valsalva maneuver: screening for drug-induced baroreflex dysfunction.

Authors:  Christoph Schroeder; Karsten Heusser; Jens Tank; André Diedrich; Friedrich C Luft; Jens Jordan
Journal:  Clin Auton Res       Date:  2008-11-15       Impact factor: 4.435

Review 3.  Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry.

Authors:  Christoph Hiemke
Journal:  Eur J Clin Pharmacol       Date:  2008-01-15       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.